How regulatory T cells keep the immune system in balance
Translational Regulation of T Regulatory Cells
This project explores how a special protein complex helps regulatory T cells form and work, which could matter for people with autoimmune diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11261239 on NIH RePORTER |
What this research studies
Researchers are studying a newly discovered protein complex called DAP5/eIF3d that controls how regulatory T cells (Tregs) make proteins. They will examine different Treg types (thymic, peripheral, and induced), chemical tags on their messenger RNA called m6A, and how these features affect Treg stability and function. The team will use lab-grown cells, molecular techniques, and studies of animal models and human-derived samples to trace how this protein-making process controls Treg behavior. The aim is to map the molecular steps that allow Tregs to develop and prevent inappropriate immune attacks on the body.
Who could benefit from this research
Good fit: People with autoimmune diseases who are willing to donate blood or tissue samples now or consider joining future Treg-targeted clinical trials are the most relevant candidates.
Not a fit: Patients whose conditions are not driven by immune overactivity or who need immediate clinical treatments are unlikely to benefit directly from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost or stabilize regulatory T cells and lead to therapies for autoimmune diseases.
How similar studies have performed: Previous laboratory work by these investigators identified the DAP5/eIF3d translation mechanism unique to Tregs, but translating this finding into therapies is new and unproven clinically.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Schneider, Robert Jay — New York University School of Medicine
- Study coordinator: Schneider, Robert Jay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.